• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases
AbstractAmong the new biological therapies for atopic diseases, dupilumab is a fully human monoclonal antibody directed against IL-4R α, the common chain of interleukin-4 and interleukin-13 receptors. Dupilumab showed clinical improvements in patients with atopic dermatitis, asthma, and chronic rhinosinusitis and is currently under development for other indications. While dupilumab is considered to be well tolerated, a number of recent publications have reported various adverse events. This review aims to summarize the current knowledge about these adverse events, which may help clinicians to improve the follow-up of pati...
Source: Clinical Reviews in Allergy and Immunology - March 11, 2022 Category: Allergy & Immunology Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Hypereosinophilia with Angioimmunoblastic T cell Lymphoma 1
A 58-year-old woman was evaluated for persistent eosinophilia. She had joint pain with effusions for 14 years and was treated for presumptive seronegative rheumatoid arthritis with prednisone and multiple disease-modifying antirheumatic drugs with minimal improvement (timeline in Figure 1). For 2.5 years prior to evaluation, she developed a persistent pruritic rash, chronic cough, and a 20 pound weight loss. She had no atopic history and was not taking any herbal supplements. She did travel to Mexico and the US Virgin Islands within the past 2 years.
Source: Annals of Allergy, Asthma and Immunology - February 6, 2020 Category: Allergy & Immunology Authors: Victoria Eng, Sameer Kumar Kulkarni, Michael Stuart Kaplan, Shefali Anil Samant, Javed Sheikh Tags: Letters Source Type: research

A case of hypereosinophilia with angioimmunoblastic T-cell lymphoma
A 58-year-old woman was evaluated for persistent eosinophilia. She had joint pain with effusions for 14 years and was treated for presumptive seronegative rheumatoid arthritis with prednisone and multiple disease-modifying antirheumatic drugs with minimal improvement (Fig 1). For 2.5 years before evaluation, she had a persistent pruritic rash, chronic cough, and a 20-lb weight loss. She had no atopic history and was not taking any herbal supplements. She had traveled to Mexico and the US Virgin Islands within the past 2 years.
Source: Annals of Allergy, Asthma and Immunology - February 6, 2020 Category: Allergy & Immunology Authors: Victoria Eng, Sameer Kumar Kulkarni, Michael Stuart Kaplan, Shefali Anil Samant, Javed Sheikh Tags: Letters Source Type: research

Hypereosinophilia with angioimmunoblastic T-cell lymphoma
A 58-year-old woman was evaluated for persistent eosinophilia. She had joint pain with effusions for 14 years and was treated for presumptive seronegative rheumatoid arthritis with prednisone and multiple disease-modifying antirheumatic drugs with minimal improvement (Fig 1). For 2.5 years before evaluation, she had a persistent pruritic rash, chronic cough, and a 20-lb weight loss. She had no atopic history and was not taking any herbal supplements. She had traveled to Mexico and the US Virgin Islands within the past 2 years.
Source: Annals of Allergy, Asthma and Immunology - February 6, 2020 Category: Allergy & Immunology Authors: Victoria Eng, Sameer Kumar Kulkarni, Michael Stuart Kaplan, Shefali Anil Samant, Javed Sheikh Tags: Letter Source Type: research

Current Clinical Trials in Pemphigus and Pemphigoid
Conclusions The clinical trials discussed here, which include several trials investigating novel therapeutic targets, demonstrate that translational research in pemphigus and pemphigoid is a fast-growing field. We thus expect that several novel treatments will be shortly available for the treatment of pemphigus and pemphigoid patients. Given the high, and thus far unmet, medical need in this field (110), this is highly encouraging and will hopefully improve the quality of life of the affected patients. In addition to the compounds and targets described here, several new targets have been recently identified in preclinical...
Source: Frontiers in Immunology - May 2, 2019 Category: Allergy & Immunology Source Type: research

Myeloid-Derived Suppressor Cells: Ductile Targets in Disease
Discussion MDSCs violently emerge in pathological conditions in an attempt to limit potentially harmful immune and inflammatory responses. Mechanisms supporting their expansion and survival are deeply investigated in cancer, in the perspective to reactivate specific antitumor responses and prevent their contribution to disease evolution. These findings will likely contribute to improve the targeting of MDSCs in anticancer immunotherapies, either alone or in combination with immune checkpoint inhibitors. New evidence indicates that the expansion of myeloid cell differentiation in pathology is subject to fine-tuning, as its...
Source: Frontiers in Immunology - May 2, 2019 Category: Allergy & Immunology Source Type: research

TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes
In conclusion, this study provides a systematic analysis of the expression of TRAIL-Rs in human primary B cells and of their capacity to signal and induce apoptosis. This dataset forms a basis to further study and understand the dysregulation of TRAIL-Rs and TRAIL expression observed in autoimmune diseases. Additionally, it will be important to foresee potential bystander immunomodulation when TRAIL-R agonists are used in cancer treatment. Introduction The homeostasis of humoral immunity requires a tight control of generation, survival, activation and maturation of B lymphocytes. Therefore, pro-survival and pro-apo...
Source: Frontiers in Immunology - April 29, 2019 Category: Allergy & Immunology Source Type: research

Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - April 29, 2019 Category: Cancer & Oncology Source Type: research

From “Serum Sickness” to “Xenosialitis”: Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human dis...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Editorial: Shaping of Human Immune System and Metabolic Processes by Viruses and Microorganisms
Conclusions In conclusion, articles in this Research Topic made a very significant contribution to our understanding of the role played by environmental factors, dysbiotic conditions, and infections in triggering diseases. Since this is a rapidly expanding area of research, many other factors contributing to the onset of these diseases are not covered here. We are confident, however, that further studies will expand the list as well as bring a better understanding of mechanisms involved in the onset of autoimmune and autoinflammatory diseases. Author Contributions All authors listed have made a substantial, direct and i...
Source: Frontiers in Microbiology - April 16, 2019 Category: Microbiology Source Type: research

“Rituximab hypersensitivity and desensitization: A personalized approach to treat cancer and connective tissue diseases”
Rituximab is a chimeric monoclonal anti-CD20 antibody with wide use in cancer (lymphoma) and connective tissue diseases (rheumatoid arthritis, and vasculitis)1. Hypersensitivity reactions to rituximab can range from type I IgE-mediated reaction (urticaria, shortness of breath, hypotension, or anaphylaxis), to cytokine-mediated reaction (fevers, chills, rigors), or a mix of both, thus limiting the use of rituximab as first line therapy for many cases. Desensitization is a new therapeutic approach which can be performed with rituximab to offset these reactions.
Source: Annals of Allergy, Asthma and Immunology - March 14, 2019 Category: Allergy & Immunology Authors: Barbara C. Yang, Mariana C. Castells Tags: Challenging Clinical Cases Source Type: research

Rituximab hypersensitivity and desensitization
Rituximab is a chimeric monoclonal anti-CD20 antibody with wide use in cancer (lymphoma) and connective tissue diseases (rheumatoid arthritis and vasculitis).1 Hypersensitivity reactions to rituximab can range from type I immunoglobulin E (IgE)-mediated reaction (urticaria, shortness of breath, hypotension, or anaphylaxis) to cytokine-mediated reaction (fevers, chills, rigors) or a mix of both, thus limiting the use of rituximab as first-line therapy for many cases. Desensitization is a new therapeutic approach that can be performed with rituximab to offset these reactions.
Source: Annals of Allergy, Asthma and Immunology - March 14, 2019 Category: Allergy & Immunology Authors: Barbara C. Yang, Mariana C. Castells Tags: Challenging Clinical Cases Source Type: research

Decursin and decursinol angelate: molecular mechanism and therapeutic potential in inflammatory diseases
AbstractEpidemiological studies have shown that inflammation plays a critical role in the development and progression of various chronic diseases, including cancers, neurological diseases, hepatic fibrosis, diabetic retinopathy, and vascular diseases. Decursin and decursinol angelate (DA) are pyranocoumarin compounds obtained from the roots ofAngelica gigas. Several studies have described the anti-inflammatory effects of decursin and DA. Decursin and DA have shown potential anti-inflammatory activity by modulating growth factors such as vascular endothelial growth factor, transcription factors such as signal transducer and...
Source: Inflammation Research - November 13, 2017 Category: Research Source Type: research

Hemophagocytic Lymphohistiocytosis mimics many common conditions: case series and review of literature.
Conclusion. Patients with HLH usually share various non-specific symptoms, such as fever and malaise, with patients across a wide spectrum of conditions: from bacterial sepsis to malignancies. Since early suspicion and diagnosis is critical to prompt therapy and improved mortality, including HLH as a possible cause of fever particularly in patients with prolonged fever of unknown origin and cytopenias will be crucial. PMID: 28120605 [PubMed - in process]
Source: European Annals of Allergy and Clinical Immunology - January 27, 2017 Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research

Pages: 1  2